BioLineRx Ltd. (NASDAQ:BLRX) Short Interest Down 47.9% in August

BioLineRx Ltd. (NASDAQ:BLRX) was the recipient of a large decrease in short interest in August. As of August 31st, there was short interest totalling 139,200 shares, a decrease of 47.9% from the August 15th total of 267,200 shares. Based on an average daily volume of 291,500 shares, the short-interest ratio is currently 0.5 days.

Analyst Upgrades and Downgrades

BLRX has been the subject of a number of research reports. HC Wainwright reiterated a “buy” rating and set a $21.00 target price on shares of BioLineRx in a report on Wednesday, May 29th. StockNews.com upgraded BioLineRx from a “sell” rating to a “hold” rating in a report on Monday, June 3rd.

Institutional Investors Weigh In On BioLineRx

Hedge funds have recently bought and sold shares of the company. NorthRock Partners LLC acquired a new stake in BioLineRx in the 4th quarter valued at about $27,000. PVG Asset Management Corp acquired a new stake in BioLineRx in the 2nd quarter valued at about $70,000. Finally, CVI Holdings LLC acquired a new stake in BioLineRx in the 2nd quarter valued at about $462,000. 1.56% of the stock is currently owned by institutional investors and hedge funds.

BioLineRx Stock Down 1.2 %

Shares of NASDAQ BLRX traded down $0.01 during mid-day trading on Friday, hitting $0.62. The company had a trading volume of 166,547 shares, compared to its average volume of 346,089. The company has a market capitalization of $49.65 million, a PE ratio of -0.82 and a beta of 1.46. The firm has a 50-day simple moving average of $0.71 and a two-hundred day simple moving average of $0.77. The company has a current ratio of 1.61, a quick ratio of 1.49 and a debt-to-equity ratio of 1.34. BioLineRx has a one year low of $0.51 and a one year high of $2.30.

BioLineRx (NASDAQ:BLRX) last issued its earnings results on Thursday, August 15th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.09. The firm had revenue of $5.39 million during the quarter, compared to analyst estimates of $3.93 million. On average, equities analysts expect that BioLineRx will post -0.25 EPS for the current year.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.